Drug Profile

601 A

Alternative Names: 601; 601-A; 601A-AMD; 601A-DME; 601A-pmCNV; 601A-RVO; Anti-VEGF monoclonal antibody - Sunshine Guojian Pharmaceutical

Latest Information Update: 16 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preregistration Diabetic macular oedema
Phase II Choroidal neovascularisation
No development reported Age-related macular degeneration; Wet age-related macular degeneration

31 Oct 2025 Preregistration for Diabetic macular oedema in China (Intravitreous)
31 Oct 2025 NMPA accepts NDA for 601 A for Diabetic macular oedema for review
23 Sep 2024 Sunshine Guojian Pharmaceutical completes a phase-III trial in Diabetic macular oedema in China (Intravitreous) (NCT05520177)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com